Comparative Pharmacology
Head-to-head clinical analysis: ATORVASTATIN CALCIUM versus BAYCOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATORVASTATIN CALCIUM versus BAYCOL.
ATORVASTATIN CALCIUM vs BAYCOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
Cerivastatin is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing hepatic cholesterol production and increasing LDL receptor expression.
10-80 mg orally once daily, starting at 10-20 mg; maximum dose 80 mg/day.
Cervastatin 0.4 mg orally once daily in the evening, with or without food.
None Documented
None Documented
Terminal elimination half-life: 14 hours (range 11–24 h); the active metabolite half-life is 20–30 h; clinical context: supports once-daily dosing despite shorter HMG-CoA reductase inhibitory half-life due to prolonged pharmacodynamic effect.
2-4 hours (terminal elimination half-life); clinical context: supports twice-daily dosing
Primarily biliary excretion (approx. 70%) as metabolites; renal excretion accounts for <2% of the administered dose; fecal elimination of metabolites and parent drug (approx. 90%).
Renal: ~70% (mostly as unchanged drug); fecal: ~15%
Category C
Category C
Statin
Statin